Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.

Abstract

Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation.

• Authors: C Martínez, E Carreras, M Rovira, A Urbano-Ispizua, J Esteve, M Perales, F Fernández, E Montserrat
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 26 Issue 6 Pg. 677-9 (Sep 2000) ISSN: 0268-3369 [Print] England
• PMID: 11035375 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cytarabine
• Granulocyte Colony-Stimulating Factor
• Etoposide
• Cyclophosphamide
• Melphalan
• Carmustine

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Carmustine
• Cyclophosphamide
• Cytarabine
• Etoposide
• Female
• Granulocyte Colony-Stimulating Factor
• Hematopoietic Stem Cell Mobilization (methods)
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Mantle-Cell (therapy)
• Male
• Melphalan
• Middle Aged
• Transplantation Conditioning (methods)
• Transplantation, Homologous
• Whole-Body Irradiation